Literature DB >> 10210218

Oncological applications of FDG PET imaging: brain tumors, colorectal cancer, lymphoma and melanoma.

D Delbeke1.   

Abstract

This article will focus primarily on body oncology diagnosis, staging and therapy monitoring using fluorodeoxyglucose (FDG) PET imaging. Common pitfalls and artifacts in body FDG imaging will be covered. Examples of diagnosis, staging and therapy monitoring of brain tumor, colorectal cancer, lymphoma and melanoma will be given. Importance of correlation with anatomic imaging and practical use of FDG imaging in patient management will be stressed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210218

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  43 in total

Review 1.  PET/CT: a new imaging technology in nuclear medicine.

Authors:  Heiko Schöder; Yusuf E Erdi; Steven M Larson; Henry W D Yeung
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-09-05       Impact factor: 9.236

2.  FDG-PET: procedure guidelines for tumour imaging.

Authors:  Emilio Bombardieri; Cumali Aktolun; Richard P Baum; Angelika Bishof-Delaloye; John Buscombe; Jean François Chatal; Lorenzo Maffioli; Roy Moncayo; Luc Mortelmans; Sven N Reske
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12       Impact factor: 9.236

3.  Multicentre assessment and monitored use of [(18)F]FDG-PET in oncology: the Spanish experience.

Authors:  Manuel Rodríguez-Garrido; Cristina Asensio-del-Barrio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-10-03       Impact factor: 9.236

4.  Thyroid incidentaloma.

Authors:  Seema Singh; Anutosh Singh; A K Khanna
Journal:  Indian J Surg Oncol       Date:  2011-11-23

Review 5.  New horizons for imaging lymphatic function.

Authors:  Ruchi Sharma; Juliet A Wendt; John C Rasmussen; Kristen E Adams; Milton V Marshall; Eva M Sevick-Muraca
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

6.  Incidental focal colorectal ¹⁸F-fluorodeoxyglucose uptake on positron emission tomography/computed tomography.

Authors:  Soung Hoon Cho; Sang Woo Kim; Won Chul Kim; Jae Myung Park; Ie Ryung Yoo; Sung Hoon Kim; Seong Taek Oh
Journal:  World J Gastroenterol       Date:  2013-06-14       Impact factor: 5.742

7.  Initial experience with FDG-PET/CT in the evaluation of breast cancer.

Authors:  Mitsuaki Tatsumi; Christian Cohade; Karen A Mourtzikos; Elliot K Fishman; Richard L Wahl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-10-29       Impact factor: 9.236

8.  [Diagnosis of chronic osteitis of the bones in the extremities. Relative value of F-18 FDG-PET].

Authors:  M Goebel; F Rosa; K Tatsch; A Grillhoesl; G O Hofmann; M H Kirschner
Journal:  Unfallchirurg       Date:  2007-10       Impact factor: 1.000

9.  Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine.

Authors:  Alexander Becherer; Georgios Karanikas; Monica Szabó; Georg Zettinig; Susanne Asenbaum; Christine Marosi; Christine Henk; Patrick Wunderbaldinger; Thomas Czech; Wolfgang Wadsak; Kurt Kletter
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-23       Impact factor: 9.236

10.  Standardized uptake value on FDG-PET as a marker for disease activity in patients with non-Hodgkin's lymphoma: comparison with serum soluble interleukin-2 receptor values.

Authors:  Mitsuaki Tatsumi; Hiroyuki Sugahara; Ichiro Higuchi; Hiroki Fukunaga; Hironobu Nakamura; Yuzuru Kanakura; Jun Hatazawa
Journal:  Int J Clin Oncol       Date:  2009-04-24       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.